| ■ 영문 제목 : Global Lung Cancer Therapeutics Market 2023-2027
|
 | ■ 상품코드 : IRTNTR71021-23
■ 조사/발행회사 : Technavio
■ 발행일 : 2022년 11월
■ 페이지수 : 약120
■ 작성언어 : 영문
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (24시간 이내)
■ 조사대상 지역 : 세계
■ 산업 분야 : 의료 기기
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1명 열람용) | USD2,500 ⇒환산￦3,500,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산￦5,600,000 | 견적의뢰/주문/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
테크나비오 조사회사는 세계의 폐암 치료 시장 규모가 2022년부터 2027년까지 연평균 7.92% 성장해 10204.33백만 달러에 달할 것으로 예측하고 있습니다. 본 조사 보고서는 세계의 폐암 치료 시장에 대해 다방면으로 조사 및 분석하여, 개요, 시장 현황, 시장 규모, 과거 시장 규모, 파이브 포스 분석, 치료법별 (표적 요법, 면역 요법, 화학 요법) 분석, 종류별 (NSCLC, SCLC) 분석, 고객 현황, 지역별 현황 (북미, 유럽, 아시아, 미국, 영국, 캐나다, 중국, 프랑스, 기타 지역) 분석, 추진 요인/과제/동향, 기업 현황, 기업 분석 등의 항목을 게재하고 있습니다. 또한 본 조사 보고서는 AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Galecto Inc., GlaxoSmithKline Plc, IOVANCE Biotherapeutics Inc., Johnson and Johnson, Merck and Co. Inc., Moderna Inc., Novartis AG, Parexel International Corp., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd. 등의 기업 정보가 수록되어 있습니다.
・개요
・시장 현황
・시장 규모
・과거 시장 규모
・파이브 포스 분석
・세계의 폐암 치료 시장 규모 : 치료법별
- 표적 요법의 시장 규모
- 면역 요법의 시장 규모
- 화학 요법의 시장 규모
・세계의 폐암 치료 시장 규모 : 종류별
- NSCLC의 시장 규모
- SCLC의 시장 규모
・고객 현황
・지역별 현황
- 북미의 폐암 치료 시장 규모
- 유럽의 폐암 치료 시장 규모
- 아시아의 폐암 치료 시장 규모
- 미국의 폐암 치료 시장 규모
- 영국의 폐암 치료 시장 규모
- 캐나다의 폐암 치료 시장 규모
- 중국의 폐암 치료 시장 규모
- 프랑스의 폐암 치료 시장 규모
- 기타 지역의 폐암 치료 시장 규모
・추진 요인/과제/동향
・기업 현황
・기업 분석
테크나비오사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 테크나비오사의 시장 조사 보고서는 정확한 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
■ 보고서 개요Global Lung Cancer Therapeutics Market 2023-2027Technavio has been monitoring the lung cancer therapeutics market and it is poised to grow by $10204.33 mn during 2023-2027, accelerating at a CAGR of 7.92% during the forecast period. Our report on the lung cancer therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the heavy contribution of immunomodulators, the strong prevalence of lung cancer, and the increasing number of patient assistance programs.
Technavio’s lung cancer therapeutics market is segmented as below:
By Therapy
• Targeted therapy
• Immunotherapy
• Chemotherapy
By Type
• NSCLC
• SCLC
By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the advent of regenerative therapies as one of the prime reasons driving the lung cancer therapeutics market growth during the next few years. Also, increasing strategic alliances and the advent of protein biomarkers will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the lung cancer therapeutics market covers the following areas:
• Lung cancer therapeutics market sizing
• Lung cancer therapeutics market forecast
• Lung cancer therapeutics market industry analysis
Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading lung cancer therapeutics market vendors that include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Galecto Inc., GlaxoSmithKline Plc, IOVANCE Biotherapeutics Inc., Johnson and Johnson, Merck and Co. Inc., Moderna Inc., Novartis AG, Parexel International Corp., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., and Boehringer Ingelheim International GmbH. Also, the lung cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
■ 보고서 목차• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global lung cancer therapeutics market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global lung cancer therapeutics market 2017 – 2021 ($ million)
o 4.2 Therapy Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Therapy Segment 2017 – 2021 ($ million)
o 4.3 Type Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Type Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Therapy
o 6.1 Market segments
o Exhibit 30: Chart on Therapy – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Therapy – Market share 2022-2027 (%)
o 6.2 Comparison by Therapy
o Exhibit 32: Chart on Comparison by Therapy
o Exhibit 33: Data Table on Comparison by Therapy
o 6.3 Targeted therapy – Market size and forecast 2022-2027
o Exhibit 34: Chart on Targeted therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Targeted therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Targeted therapy – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Targeted therapy – Year-over-year growth 2022-2027 (%)
o 6.4 Immunotherapy – Market size and forecast 2022-2027
o Exhibit 38: Chart on Immunotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Immunotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Immunotherapy – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Immunotherapy – Year-over-year growth 2022-2027 (%)
o 6.5 Chemotherapy – Market size and forecast 2022-2027
o Exhibit 42: Chart on Chemotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on Chemotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on Chemotherapy – Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on Chemotherapy – Year-over-year growth 2022-2027 (%)
o 6.6 Market opportunity by Therapy
o Exhibit 46: Market opportunity by Therapy ($ million)
• 7 Market Segmentation by Type
o 7.1 Market segments
o Exhibit 47: Chart on Type – Market share 2022-2027 (%)
o Exhibit 48: Data Table on Type – Market share 2022-2027 (%)
o 7.2 Comparison by Type
o Exhibit 49: Chart on Comparison by Type
o Exhibit 50: Data Table on Comparison by Type
o 7.3 NSCLC – Market size and forecast 2022-2027
o Exhibit 51: Chart on NSCLC – Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Data Table on NSCLC – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Chart on NSCLC – Year-over-year growth 2022-2027 (%)
o Exhibit 54: Data Table on NSCLC – Year-over-year growth 2022-2027 (%)
o 7.4 SCLC – Market size and forecast 2022-2027
o Exhibit 55: Chart on SCLC – Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on SCLC – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on SCLC – Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on SCLC – Year-over-year growth 2022-2027 (%)
o 7.5 Market opportunity by Type
o Exhibit 59: Market opportunity by Type ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 61: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 63: Chart on Geographic comparison
o Exhibit 64: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 65: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 66: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 67: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 68: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 69: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 70: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 71: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 72: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 73: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 77: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 81: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 UK – Market size and forecast 2022-2027
o Exhibit 85: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.9 Canada – Market size and forecast 2022-2027
o Exhibit 89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.10 China – Market size and forecast 2022-2027
o Exhibit 93: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.11 France – Market size and forecast 2022-2027
o Exhibit 97: Chart on France – Market size and forecast 2022-2027 ($ million)
o Exhibit 98: Data Table on France – Market size and forecast 2022-2027 ($ million)
o Exhibit 99: Chart on France – Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on France – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 101: Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 102: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 104: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 105: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 106: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 107: Matrix on vendor position and classification
o 12.3 AbbVie Inc.
o Exhibit 108: AbbVie Inc. – Overview
o Exhibit 109: AbbVie Inc. – Product / Service
o Exhibit 110: AbbVie Inc. – Key offerings
o 12.4 Amgen Inc.
o Exhibit 111: Amgen Inc. – Overview
o Exhibit 112: Amgen Inc. – Product / Service
o Exhibit 113: Amgen Inc. – Key offerings
o 12.5 Astellas Pharma Inc.
o Exhibit 114: Astellas Pharma Inc. – Overview
o Exhibit 115: Astellas Pharma Inc. – Product / Service
o Exhibit 116: Astellas Pharma Inc. – Key news
o Exhibit 117: Astellas Pharma Inc. – Key offerings
o 12.6 AstraZeneca Plc
o Exhibit 118: AstraZeneca Plc – Overview
o Exhibit 119: AstraZeneca Plc – Product / Service
o Exhibit 120: AstraZeneca Plc – Key news
o Exhibit 121: AstraZeneca Plc – Key offerings
o 12.7 Boehringer Ingelheim International GmbH
o Exhibit 122: Boehringer Ingelheim International GmbH – Overview
o Exhibit 123: Boehringer Ingelheim International GmbH – Business segments
o Exhibit 124: Boehringer Ingelheim International GmbH – Key news
o Exhibit 125: Boehringer Ingelheim International GmbH – Key offerings
o Exhibit 126: Boehringer Ingelheim International GmbH – Segment focus
o 12.8 Bristol Myers Squibb Co.
o Exhibit 127: Bristol Myers Squibb Co. – Overview
o Exhibit 128: Bristol Myers Squibb Co. – Product / Service
o Exhibit 129: Bristol Myers Squibb Co. – Key offerings
o 12.9 Daiichi Sankyo Co. Ltd.
o Exhibit 130: Daiichi Sankyo Co. Ltd. – Overview
o Exhibit 131: Daiichi Sankyo Co. Ltd. – Business segments
o Exhibit 132: Daiichi Sankyo Co. Ltd. – Key news
o Exhibit 133: Daiichi Sankyo Co. Ltd. – Key offerings
o Exhibit 134: Daiichi Sankyo Co. Ltd. – Segment focus
o 12.10 Eli Lilly and Co.
o Exhibit 135: Eli Lilly and Co. – Overview
o Exhibit 136: Eli Lilly and Co. – Product / Service
o Exhibit 137: Eli Lilly and Co. – Key offerings
o 12.11 F. Hoffmann La Roche Ltd.
o Exhibit 138: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 139: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 140: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 141: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 142: F. Hoffmann La Roche Ltd. – Segment focus
o 12.12 GlaxoSmithKline Plc
o Exhibit 143: GlaxoSmithKline Plc – Overview
o Exhibit 144: GlaxoSmithKline Plc – Business segments
o Exhibit 145: GlaxoSmithKline Plc – Key offerings
o Exhibit 146: GlaxoSmithKline Plc – Segment focus
o 12.13 Merck and Co. Inc.
o Exhibit 147: Merck and Co. Inc. – Overview
o Exhibit 148: Merck and Co. Inc. – Business segments
o Exhibit 149: Merck and Co. Inc. – Key news
o Exhibit 150: Merck and Co. Inc. – Key offerings
o Exhibit 151: Merck and Co. Inc. – Segment focus
o 12.14 Novartis AG
o Exhibit 152: Novartis AG – Overview
o Exhibit 153: Novartis AG – Business segments
o Exhibit 154: Novartis AG – Key offerings
o Exhibit 155: Novartis AG – Segment focus
o 12.15 Pfizer Inc.
o Exhibit 156: Pfizer Inc. – Overview
o Exhibit 157: Pfizer Inc. – Product / Service
o Exhibit 158: Pfizer Inc. – Key news
o Exhibit 159: Pfizer Inc. – Key offerings
o 12.16 Sanofi SA
o Exhibit 160: Sanofi SA – Overview
o Exhibit 161: Sanofi SA – Business segments
o Exhibit 162: Sanofi SA – Key news
o Exhibit 163: Sanofi SA – Key offerings
o Exhibit 164: Sanofi SA – Segment focus
o 12.17 Takeda Pharmaceutical Co. Ltd.
o Exhibit 165: Takeda Pharmaceutical Co. Ltd. – Overview
o Exhibit 166: Takeda Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 167: Takeda Pharmaceutical Co. Ltd. – Key news
o Exhibit 168: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 169: Inclusions checklist
o Exhibit 170: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 171: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 172: Research methodology
o Exhibit 173: Validation techniques employed for market sizing
o Exhibit 174: Information sources
o 13.5 List of abbreviations
o Exhibit 175: List of abbreviations
Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Therapy
Exhibits6: Executive Summary – Chart on Market Segmentation by Type
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global lung cancer therapeutics market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Therapy Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Type Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Therapy – Market share 2022-2027 (%)
Exhibits31: Data Table on Therapy – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Therapy
Exhibits33: Data Table on Comparison by Therapy
Exhibits34: Chart on Targeted therapy – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Targeted therapy – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Targeted therapy – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Targeted therapy – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Immunotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Immunotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Immunotherapy – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Immunotherapy – Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on Chemotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on Chemotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on Chemotherapy – Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on Chemotherapy – Year-over-year growth 2022-2027 (%)
Exhibits46: Market opportunity by Therapy ($ million)
Exhibits47: Chart on Type – Market share 2022-2027 (%)
Exhibits48: Data Table on Type – Market share 2022-2027 (%)
Exhibits49: Chart on Comparison by Type
Exhibits50: Data Table on Comparison by Type
Exhibits51: Chart on NSCLC – Market size and forecast 2022-2027 ($ million)
Exhibits52: Data Table on NSCLC – Market size and forecast 2022-2027 ($ million)
Exhibits53: Chart on NSCLC – Year-over-year growth 2022-2027 (%)
Exhibits54: Data Table on NSCLC – Year-over-year growth 2022-2027 (%)
Exhibits55: Chart on SCLC – Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on SCLC – Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on SCLC – Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on SCLC – Year-over-year growth 2022-2027 (%)
Exhibits59: Market opportunity by Type ($ million)
Exhibits60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits61: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits63: Chart on Geographic comparison
Exhibits64: Data Table on Geographic comparison
Exhibits65: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits66: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits67: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits68: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits69: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits70: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits71: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits72: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits73: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on France – Market size and forecast 2022-2027 ($ million)
Exhibits98: Data Table on France – Market size and forecast 2022-2027 ($ million)
Exhibits99: Chart on France – Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on France – Year-over-year growth 2022-2027 (%)
Exhibits101: Market opportunity By Geographical Landscape ($ million)
Exhibits102: Impact of drivers and challenges in 2022 and 2027
Exhibits103: Overview on Criticality of inputs and Factors of differentiation
Exhibits104: Overview on factors of disruption
Exhibits105: Impact of key risks on business
Exhibits106: Vendors covered
Exhibits107: Matrix on vendor position and classification
Exhibits108: AbbVie Inc. – Overview
Exhibits109: AbbVie Inc. – Product / Service
Exhibits110: AbbVie Inc. – Key offerings
Exhibits111: Amgen Inc. – Overview
Exhibits112: Amgen Inc. – Product / Service
Exhibits113: Amgen Inc. – Key offerings
Exhibits114: Astellas Pharma Inc. – Overview
Exhibits115: Astellas Pharma Inc. – Product / Service
Exhibits116: Astellas Pharma Inc. – Key news
Exhibits117: Astellas Pharma Inc. – Key offerings
Exhibits118: AstraZeneca Plc – Overview
Exhibits119: AstraZeneca Plc – Product / Service
Exhibits120: AstraZeneca Plc – Key news
Exhibits121: AstraZeneca Plc – Key offerings
Exhibits122: Boehringer Ingelheim International GmbH – Overview
Exhibits123: Boehringer Ingelheim International GmbH – Business segments
Exhibits124: Boehringer Ingelheim International GmbH – Key news
Exhibits125: Boehringer Ingelheim International GmbH – Key offerings
Exhibits126: Boehringer Ingelheim International GmbH – Segment focus
Exhibits127: Bristol Myers Squibb Co. – Overview
Exhibits128: Bristol Myers Squibb Co. – Product / Service
Exhibits129: Bristol Myers Squibb Co. – Key offerings
Exhibits130: Daiichi Sankyo Co. Ltd. – Overview
Exhibits131: Daiichi Sankyo Co. Ltd. – Business segments
Exhibits132: Daiichi Sankyo Co. Ltd. – Key news
Exhibits133: Daiichi Sankyo Co. Ltd. – Key offerings
Exhibits134: Daiichi Sankyo Co. Ltd. – Segment focus
Exhibits135: Eli Lilly and Co. – Overview
Exhibits136: Eli Lilly and Co. – Product / Service
Exhibits137: Eli Lilly and Co. – Key offerings
Exhibits138: F. Hoffmann La Roche Ltd. – Overview
Exhibits139: F. Hoffmann La Roche Ltd. – Business segments
Exhibits140: F. Hoffmann La Roche Ltd. – Key news
Exhibits141: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits142: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits143: GlaxoSmithKline Plc – Overview
Exhibits144: GlaxoSmithKline Plc – Business segments
Exhibits145: GlaxoSmithKline Plc – Key offerings
Exhibits146: GlaxoSmithKline Plc – Segment focus
Exhibits147: Merck and Co. Inc. – Overview
Exhibits148: Merck and Co. Inc. – Business segments
Exhibits149: Merck and Co. Inc. – Key news
Exhibits150: Merck and Co. Inc. – Key offerings
Exhibits151: Merck and Co. Inc. – Segment focus
Exhibits152: Novartis AG – Overview
Exhibits153: Novartis AG – Business segments
Exhibits154: Novartis AG – Key offerings
Exhibits155: Novartis AG – Segment focus
Exhibits156: Pfizer Inc. – Overview
Exhibits157: Pfizer Inc. – Product / Service
Exhibits158: Pfizer Inc. – Key news
Exhibits159: Pfizer Inc. – Key offerings
Exhibits160: Sanofi SA – Overview
Exhibits161: Sanofi SA – Business segments
Exhibits162: Sanofi SA – Key news
Exhibits163: Sanofi SA – Key offerings
Exhibits164: Sanofi SA – Segment focus
Exhibits165: Takeda Pharmaceutical Co. Ltd. – Overview
Exhibits166: Takeda Pharmaceutical Co. Ltd. – Product / Service
Exhibits167: Takeda Pharmaceutical Co. Ltd. – Key news
Exhibits168: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibits169: Inclusions checklist
Exhibits170: Exclusions checklist
Exhibits171: Currency conversion rates for US$
Exhibits172: Research methodology
Exhibits173: Validation techniques employed for market sizing
Exhibits174: Information sources
Exhibits175: List of abbreviations
|
| ※본 조사보고서 [세계의 폐암 치료 시장 (2023년~2027년)] (코드 : IRTNTR71021-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 폐암 치료 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요! 세계의 폐암 치료 시장 (2023년~2027년)
